Hoth Therapeutics, Inc. announced that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001. This First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose-ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for thetreatment of skin toxicities associated with EGFRi.

More information can be found at clinicaltrials.gov.